Changing the future of skincare for a brighter tomorrow

As a drug discovery bioventure company engaging in pioneering R&D on a
global scale, Abrax proposes an unprecedented skin improvement method
utilizing TSLP (thymic stromal lymphopoietin).
The company is not only developing pharmaceuticals for the treatment of
eczema, but also planning to develop new formulations for other pipeline
drugs and skincare products utilizing TSLP technology in the near future.
We firmly believe these plans will help Abrax expand its product and
service portfolio indefinitely and drastically enhance the value and
presence of Abrax in the healthcare and skincare markets.